Allarity Therapeutics, Inc. raised approximately $3.15 million by selling 35,000 shares of Series A Convertible Redeemable Preferred Stock at $90 each, and extended its license agreement with Eisai for Stenoparib, with a deadline for a Phase 2 Clinical Trial completion set for April 1, 2028.